Moss, 17 August 2018
Gentian Diagnostics AS announces its results for the second quarter and first half year. The highlights of the quarter include:
- 37% revenue growth vs 1H 2017
- fCAL turbo and CCRP with record sales in 2Q18
- Proof of concept achieved for new pancreatic elastase assay
- Share issue with net proceeds of MNOK 68.5
Please find the report for the second quarter and first half year enclosed. The report will also be made available on www.gentian.no.
For further information, please contact:
Bård Sundrehagen
EVP Business Development, Gentian Diagnostics
E-mail: Bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525
MeldingsID: 457417
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: HALVÅRSRAPPORTER OG REVISJONSBERETNINGER / UTTALELSER OM FORENKLET REVISORKONTROLL
Informasjonspliktige opplysninger: Ja
Vedlegg: GDAS 2018 2Q Interim report (1)